Abivax

Centre National De La Recherche Scientifique

Universitè De Montpellier

Institut Curie

Universite Montpellier 2

Societe Splicos

Abivax Sa

Didier Scherrer

Jamal Tazi

Romain Najman

Florence Mahuteau

Aude Garcel

Pierre Roux

Julien Santo

Noelie Campos

Gilles Gadea

Nathalie Cahuzac

Carsten Brock

Cécile Apolit

Florence Mahuteau-Betzer

Philippe Pouletty

Florence Mahuteau-betzer

Hartmut Ehrlich

Noëlie Campos

Audrey Vautrin

Pauline Fornarelli

Sandrine Crabe

Karim Chebli

Michael Hahne

Julian Venables

Noëlle Campos

Frederic Labeguere

Brice Sautier

Natacha Bienvenu

Elisa Azzali

A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification wherein Rrepresents a chlorine atom or a hydrogen atom, R represents a (C-C)alkyl group, a (C-C)cycloalkyl group, a halogen atom, a (C-C)alkoxy group, a —SO—NRRgroup, a —SOH group, a —OH group, a —O—SO—ORgroup or a —O—P(═O)—(OR)(OR) group, Rrepresents (i) a CFgroup, (ii) a (C-C)alkyl group, (iii) a (C-C)cycloalkyl or a (C-C)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and Rrepresents a hydrogen atom, a (C-C)alkyl group, a (C-C)cycloalkyl or a (C-C)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

Phenyl-n-quinoline derivatives for treating a RNA virus infection

A compound of formula (Ie): wherein Yrepresents an aryl group, Xrepresents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH)NH— group, a —C(OH)(CHOH)—, a group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO— group, or a —SO—NH— group, Yrepresents a hydrogen atom, a hydroxyl group, a (C-C)alkoxy group, a —CHC(OH), a COOR, wherein Rrepresents a hydrogen atom or a (C-C)alkyl group, a morpholinyl group, a dihydropyranyl group, a group, a group, a —PO(OR)(OR') group, wherein Rand R′independently represents a hydrogen atom or a (C-C)alkyl group, an oxetanyl group, a —Si(CH)group, a —NHCOO—(C-C)alkyl group, or a —CRRRgroup, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.

Aryl-n-aryl derivatives for treating a RNA virus infection

A compound of formula (Ic) a group, a group, a morpholinyl group, optionally substituted by a (C-C)alkyl group, a piperazinyl group, a piperidinyl group, or a —CRRRgroup, or any of its pharmaceutically acceptable salt.

In vitro or ex vivo methods for screening a quinoline derivative, or anyone of its pharmaceutically acceptable salt, presumed effective in treating and/or preventing an inflammatory disease, the method including: providing an eukaryotic cell, bringing into contact said cell with a quinoline derivative, measuring an expression of miR-124 in the cell, and selecting the candidate presumed effective in treating and/or preventing an inflammatory disease when the level of expression of miR-124 measured is increased relatively to a reference value.

In vitro or ex vivo methods for screening a quinoline derivative

A compound of Formula (I): or anyone of its metabolites or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein each R is independently hydrogen, halogen, —CN, hydroxyl, (C-C)fluoroalkyl, (C-C)fluoroalkoxy, (C-C)cycloalkyl, —NO, —NRR, (C-C)alkoxy, phenoxy, —NR—SO—NRR, —NR—SO—R1, —NR—C(═O)—R, —NR—C(═O)—NRR, —SO—NRR, —SOH, —O—SO—OR, —O—P(═O)—(OR)(OR), —O—CH—COOR, (C-C)alkyl; each R' is independently hydrogen, (C1-C3)alkyl, hydroxyl, halogen, —NO, —NRR, morpholinyl, morpholino, N-methylpiperazinyl, (C-C)fluoroalkyl, (C-C)alkoxy, —O—P(═O)—(OR)(OR), —CN, a —NH—SO—N(CH)group, or other groups and further relates to A compound of formula (IV): or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein V, Z, R, R', n, and n′ are as described above.

Quinoline derivatives for use in the treatment of inflammation diseases

An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.

Combinations including ABX196 for the treatment of cancer

A compound: wherein Xrepresents an alkenylene group, a &#x2014;NH&#x2014;CO&#x2014; group, a &#x2014;CO&#x2014;NH&#x2014; group, Yrepresents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, Xrepresents &#x2014;O&#x2014;, &#x2014;CO&#x2014;NH&#x2014;, &#x2014;NH&#x2014;CO&#x2014;NH&#x2014;, &#x2014;OCH&#x2014;, &#x2014;NH&#x2014;CO&#x2014;, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or &#x2014;SO&#x2014;NH&#x2014;, and Yrepresents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C-C)alkyl group, a piperazinyl group, optionally substituted by a (C-C)alkyl group, or &#x2014;CRRRor alternatively X&#x2014;Yrepresents &#x2014;CONRR, wherein Rand Rform, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C-C)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.

The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R&#x2033; does not exist when Q is O; R' independently represent a hydrogen atom or a group chosen among a (C-C)alkyl group, a halogen atom, a hydroxyl group, a &#x2014;COORgroup, a &#x2014;NOgroup, a &#x2014;NRRgroup, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C-C)fluoroalkyl group, a &#x2014;O&#x2014;P(&#x2550;O)&#x2014;(OR)(OR) group, a (C-C)alkoxy group and a &#x2014;CN group, and can further be a group chosen among: 

Use of quinoline derivatives for the treatment of inflammatory diseases

A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.

miRNA-124 as a biomarker

A compound of formula (I): wherein A and A' independently represent a phenylene group or a pyridylene group; Ris a hydrogen atom or a (C-C)alkyl group; Ris a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; Ris a carbonyl group or a sulfonyl group; and Ris a &#x2014;NH&#x2014;(CH)&#x2014;NRRgroup or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, Rand Rrepresenting independently a (C-C)alkyl group, or Rand Rtogether with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.

Compounds useful for treating cancer

The compound ABX196 and pharmaceutical compositions including ABX196 are used in the treatment of bladder cancer.

ABX196 for use in the treatment of bladder cancer

The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.

Growing community of inventors

Castelnau le Lez, France

Didier Scherrer